The ultimate objective of the government's program is to develop a safe and effective vaccine to protect against the Zaire, Sudan and Cote d'Ivoire strains of Ebola virus as well as multiple isolates of Marburg virus. The vaccine, to be developed by IBT, provides broad protection in nonhuman primates. The virus-like particle vaccines are strikingly similar to the authentic virus and were originally developed by IBT's founders and their colleagues at USAMRIID.
Initially, IBT will receive approximately $22 million to conduct preclinical activities, including preclinical efficacy animal studies, development and qualification of assays, formulation studies and process development for manufacturing activities. After preclinical studies, NIAID may exercise options to the contract that include cGMP manufacturing, Phase 1 clinical trial, scale-up of cGMP manufacturing, lyophylized formulation and a Phase 2 clinical trial The potential value of the entire contract if all the options are exercised by the government, is $65.2 million.
About Integrated BioTherapeutics Inc.:
Integrated BioTherapeutics Inc. (IBT) is an emerging research-based
company dedicated to development of vaccines, immunotherapeutics, and
discovery of small molecules targeting emerging infectious agents. IBT is
located in Germantown, Maryland. IBT has a portfolio of proprietary
recombinant technologies for development of vaccines and immunotherapeutics
against major biodefense and emerging infectious agents, with an emphasis
on staphylococcal, and streptococcal infections, as well as viral
hemorrhagic fevers. IBT has experience and a close working arrangement with
many of the United States government agencies including the United States
Army Medical Research Institute of Infectious
|SOURCE Integrated BioTherapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved